JP6284541B2 - 長時間作用型トポイソメラーゼi阻害薬による乳癌治療の有効性を評価及び予測する方法 - Google Patents

長時間作用型トポイソメラーゼi阻害薬による乳癌治療の有効性を評価及び予測する方法 Download PDF

Info

Publication number
JP6284541B2
JP6284541B2 JP2015544204A JP2015544204A JP6284541B2 JP 6284541 B2 JP6284541 B2 JP 6284541B2 JP 2015544204 A JP2015544204 A JP 2015544204A JP 2015544204 A JP2015544204 A JP 2015544204A JP 6284541 B2 JP6284541 B2 JP 6284541B2
Authority
JP
Japan
Prior art keywords
weeks
long
treatment
inhibitor
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015544204A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016502083A (ja
JP2016502083A5 (enExample
Inventor
イェン リン チア,
イェン リン チア,
ウテ ホック,
ウテ ホック,
アリソン ハンナ,
アリソン ハンナ,
マイケル エー. エルドン,
マイケル エー. エルドン,
Original Assignee
ネクター セラピューティクス
ネクター セラピューティクス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ネクター セラピューティクス, ネクター セラピューティクス filed Critical ネクター セラピューティクス
Publication of JP2016502083A publication Critical patent/JP2016502083A/ja
Publication of JP2016502083A5 publication Critical patent/JP2016502083A5/ja
Application granted granted Critical
Publication of JP6284541B2 publication Critical patent/JP6284541B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57415Specifically defined cancers of breast
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4725Mucins, e.g. human intestinal mucin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2015544204A 2012-11-28 2013-11-27 長時間作用型トポイソメラーゼi阻害薬による乳癌治療の有効性を評価及び予測する方法 Active JP6284541B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261730900P 2012-11-28 2012-11-28
US61/730,900 2012-11-28
PCT/US2013/072205 WO2014085571A1 (en) 2012-11-28 2013-11-27 Method for assessing and predicting efficacy of breast cancer treatment with a long-acting topoisomerase i inhibitor

Publications (3)

Publication Number Publication Date
JP2016502083A JP2016502083A (ja) 2016-01-21
JP2016502083A5 JP2016502083A5 (enExample) 2016-11-17
JP6284541B2 true JP6284541B2 (ja) 2018-02-28

Family

ID=49753531

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015544204A Active JP6284541B2 (ja) 2012-11-28 2013-11-27 長時間作用型トポイソメラーゼi阻害薬による乳癌治療の有効性を評価及び予測する方法

Country Status (10)

Country Link
US (2) US10132810B2 (enExample)
EP (1) EP2926137B1 (enExample)
JP (1) JP6284541B2 (enExample)
KR (1) KR102120510B1 (enExample)
CN (1) CN104813167B (enExample)
AU (1) AU2013352223B2 (enExample)
CA (1) CA2890082C (enExample)
ES (1) ES2731725T3 (enExample)
MX (1) MX366911B (enExample)
WO (1) WO2014085571A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106191022B (zh) * 2016-02-22 2019-08-20 叶尚勉 一种肿瘤特异抗原及其应用
US11253603B2 (en) 2018-09-17 2022-02-22 The Children's Hospital Of Philadelphia Polymer-based macromolecular prodrugs
CN112102914A (zh) * 2020-09-25 2020-12-18 复旦大学附属肿瘤医院 曲妥珠单抗生物类似药的评价方法及系统

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9704444D0 (en) * 1997-03-04 1997-04-23 Isis Innovation Non-invasive prenatal diagnosis
US6355623B2 (en) * 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
US20020103141A1 (en) * 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
CN1852740B (zh) 2003-09-17 2011-05-11 耐科塔医药公司 多支链聚合物的药物前体
JP2007526455A (ja) * 2004-02-03 2007-09-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を特徴付ける、制御する、診断する、および処置するための組成物ならびに方法
EP1928484B1 (en) * 2005-08-26 2010-02-24 The Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of headaches by administration of oxytocin
CA2640013A1 (en) * 2006-02-09 2007-08-16 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
US20110151580A1 (en) * 2007-11-06 2011-06-23 University Health Network Method for the detection of breast cancer by determining alcam and/or bcam levels in a patient
RS59607B1 (sr) * 2008-09-23 2020-01-31 Nektar Therapeutics Metod metronomskog doziranja kamptotecinskih prolekova (npr. peg-irinotekan)
EP2501412B1 (en) 2009-11-18 2017-03-29 Nektar Therapeutics Salt form of a multi-arm polymer-drug conjugate
CA2795776A1 (en) * 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
WO2012031320A1 (en) 2010-09-06 2012-03-15 Peter Maccallum Cancer Institute Cancer diagnostic
US20140378404A1 (en) 2011-10-25 2014-12-25 Nektar Therapeutics Treatment of Patients Suffering from Cancer

Also Published As

Publication number Publication date
JP2016502083A (ja) 2016-01-21
AU2013352223B2 (en) 2019-07-18
MX2015006733A (es) 2015-08-14
CN104813167B (zh) 2019-04-09
KR20150089013A (ko) 2015-08-04
WO2014085571A1 (en) 2014-06-05
US20190049450A1 (en) 2019-02-14
MX366911B (es) 2019-07-30
KR102120510B1 (ko) 2020-06-08
ES2731725T3 (es) 2019-11-18
US10132810B2 (en) 2018-11-20
CN104813167A (zh) 2015-07-29
CA2890082C (en) 2021-07-06
US20150309032A1 (en) 2015-10-29
EP2926137B1 (en) 2019-05-29
AU2013352223A1 (en) 2015-05-21
EP2926137A1 (en) 2015-10-07
CA2890082A1 (en) 2014-06-05

Similar Documents

Publication Publication Date Title
US11844795B2 (en) Combination therapy for cancer treatment
Wolfgang et al. Recent progress in pancreatic cancer
Wolpin et al. Adjuvant treatment of colorectal cancer
Prados et al. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study
KR102606071B1 (ko) 상피양 세포 종양을 치료하는 방법
Sanford et al. Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer
Maity et al. Targeting the epidermal growth factor receptor with molecular degraders: state-of-the-art and future opportunities
US20190049450A1 (en) Method for Assessing and Predicting Efficacy of Breast Cancer Treatment with a Long-Acting Topoisomerase I Inhibitor
US20180095085A1 (en) Method for predicting and evaluating responsiveness to cancer treatment with dna-damaging chemotherapeutic agents
JP2024502446A (ja) 癌の治療におけるkras g12c阻害剤の使用
Beer et al. Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy
Srinivas et al. A phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinoma
US20150374672A1 (en) Pre-selection of subjects for therapeutic treatment with an hsp90 inhibitory compound based on chemosensitive status
Graham et al. A multi-centre dose-escalation and pharmacokinetic study of diflomotecan in patients with advanced malignancy
Guzman et al. P-264 Helicobacter pylori SNPs associated with tetracycline, clarithromycin and amoxicillin resistance in Colombia
Lanki Prognostic and differential diagnostic biomarkers in pancreatic ductal adenocarcinoma
Nimmagadda et al. Raf kinase inhibitors for the treatment of melanoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160926

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160926

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170622

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171010

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180129

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180130

R150 Certificate of patent or registration of utility model

Ref document number: 6284541

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250